Recombinant Human ARHI Protein (Fc Tag)

Beta LifeScience SKU/CAT #: BLPSN-0257

Recombinant Human ARHI Protein (Fc Tag)

Beta LifeScience SKU/CAT #: BLPSN-0257
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Tag Fc
Host Species Human
Accession O95661
Background ARHI, also known as DIRAS3, belongs to the small GTPase superfamily, Di-Ras family. ARHI gene is a novel tumor suppressor gene located on chromosome 1p31. Downregulation of ARHI expression has been detected in many types of cancer. ARHI is expressed in normal ovarian and breast epithelial cells but not in ovarian and breast cancers. As a suppressor, ARHI is not only an important factor in the pathogenesis of gastric cancer, but also a potential factor for tumor aggravation. ARHI expression in gastric cancer can be employed to indicate favorable prognosis for the disease.
Description A DNA sequence encoding the human DIRAS3 (O95661) (Met1-Lys225) was expressed with the Fc region of mouse IgG1 at the N-terminus.
Source HEK293
Predicted N Terminal Asp
AA Sequence Met1-Lys225
Molecular Weight The recombinant human DIRAS3/mFc comprises 461 a.a. and has a predicted molecular mass of 52.1 kDa. The apparent molecular mass of the monomer is approximately 62 kDa in SDS-PAGE under reducing conditions due to glycosylation.
Purity >85% as determined by SDS-PAGE
Endotoxin < 1.0 EU per μg of the protein as determined by the LAL method
Bioactivity Please contact us for detailed information
Formulation Lyophilized from sterile PBS, pH 7.4..
Stability The recombinant proteins are stable for up to 1 year from date of receipt at -70°C.
Usage For Research Use Only
Storage Store the protein under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

Target Details

Subcellular Location Cell membrane; Lipid-anchor; Cytoplasmic side.
Protein Families Small GTPase superfamily, Di-Ras family
Database References
Tissue Specificity Expressed in normal ovarian and breast epithelial cells but not in ovarian and breast cancers.

Gene Functions References

  1. Low DIRAS3 expression is associated with metastasis in gastric cancer. PMID: 30043279
  2. lncRNA GAS5 functions as a competing endogenous RNA for miR-221 to suppress cell growth and EMT in osteosarcoma by regulating the miR-221/ARHI pathway. PMID: 28519068
  3. DiRas3 binds to KSR1 independently of its interaction with activated Ras and RAF. PMID: 27368419
  4. We demonstrate that DIRAS3 knock-down (KD) in adipose stromal/progenitor cells (ASCs) induces activation of Akt-mTOR signaling and proliferation arrest. DIRAS3 KD ASCs lose the potential to form colonies and are negative for Ki-67. Moreover, silencing of DIRAS3 results in a premature senescence phenotype. PMID: 28316325
  5. ARHI-mediated up-regulation of glycolysis and glutaminolysis was found to be autophagy-dependent and inhibition of these metabolic pathways resulted in decreased cell viability. PMID: 27784287
  6. The overexpression of ARHI promotes colon cancer SW480 cell apoptosis by inhibiting the level of Akt. PMID: 27774944
  7. Transcriptional, but not post-transcriptional, silencing of GNG12-AS1 causes concomitant upregulation of DIRAS3, indicating a function in transcriptional interference. PMID: 26832224
  8. ARHI mRNA and protein expression is markedly decreased in osteosarcoma MG-63 cells lines. Overexpression of ARHI inhibits cell viability and proliferation. PMID: 26165148
  9. ARHI-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts. PMID: 26247722
  10. EZH2-''induced H3K27me3 is associated with epigenetic repression of the ARHI tumor-suppressor gene in epithelial ovarian cancer PMID: 25077680
  11. ARHI competes with RanGTPase and interacts with importin beta via basic-acidic patch interaction, which leads to inhibition of STAT3 translocation. PMID: 25499977
  12. Letter: ARHI suppresses pancreatic cancer by regulating ERK 1/2 signaling. PMID: 25675421
  13. JMJD2A-dependent silencing of Sp1 in advanced breast cancer promotes metastasis by downregulation of DIRAS3. PMID: 25193278
  14. suggest that DIRAS3 not only regulates the autophagosome initiation complex, but induces autophagy in dormant, nutrient-deprived ovarian cancer cells that remain after conventional chemotherapy, facilitating their survival PMID: 24879154
  15. ARHI is required for autophagy-meditated cancer cell arrest and ARHI inhibits signaling through PI3K/AKT and Ras/MAP by enhancing internalization and degradation of the epidermal growth factor receptor. PMID: 24769729
  16. The silence of ARHI expression in vitro seems to accelerate the malignant transformation of healthy ovarian cells by restraining apoptosis and autophagy. PMID: 24476894
  17. ARHI acts as a tumor suppressor gene in MDA-MB-231 cells and, although trichostatin A+5-aza-2'-deoxycytidine can block the cells at different cell cycle phase, the antitumor effect is ARHI-dependent. PMID: 24676336
  18. Loss of ARHI expression is associated with glioma. PMID: 24458808
  19. ARHI acts as a tumor suppressor by downregulating the NFkappaB signaling pathway, which results in the inhibition of cell proliferation, apoptosis and the cell cycle in the pancreatic tumor PANC-1 cell line PMID: 23447002
  20. overexpression of ARHI gene might be associated with the inhibition of lung cancer cell growth, proliferation and invasion, and the promotion of apoptosis. PMID: 23247805
  21. Results indicate that the aplysia ras homolog member I (ARHI) 3'UTR was a direct target of miR-221 in breast cancer MCF-7 cells. PMID: 23801152
  22. acetylated STAT3 bound to the ARHI promoter and recruited DNA methyltransferase 1 for genetic modification. PMID: 23604529
  23. Imprinted chromatin around DIRAS3 regulates alternative splicing of GNG12-AS1, a long noncoding RNA. PMID: 23871723
  24. Expression of JMJD2A in infiltrating duct carcinoma is higher than in fibroadenoma, and is associated with ARHI, p53 and ER PMID: 23678541
  25. DiRas3 interacts with C-RAF and downregulates MEK1 activity to restrict cell migration. PMID: 23157514
  26. ARHI expression is present in the endometrium and up-regulated in ectopic endometrium, whereas in the ectopic endometrium of patients with malignant endometriosis its expression is often negative. PMID: 21602127
  27. ARHI expression is downregulated in human gastric cancer and it may be a novel tumor suppressive target for gastric cancer therapy. PMID: 22497484
  28. The consequence of complex formation is a DiRas3-mediated recruitment and anchorage of C-RAF to components of the membrane skeleton, suppression of C-RAF/B-RAF heterodimerization, and inhibition of C-RAF kinase activity. PMID: 22605333
  29. downregulation of ARHI may play an important role both in the pathogenesis and aggravation of gastric cancer. ARHI gene CpG island methylation is a potential molecular basis of its downregulation. PMID: 22427032
  30. The level of ARHI mRNA was significantly lower in aggressive compared with non-aggressive prostate cancer tissue samples PMID: 22117988
  31. ARHI has a critical and previously uncharacterized role in the regulation of ovarian cancer cell migration. PMID: 21643014
  32. ARHI has pro-apoptotic effects on HCC cells, which is associated with the inactivation of both Akt and NF-kappaB survival pathways. PMID: 21933150
  33. Data show that ARHI re-expression induces autophagic cell death in breast cancer cells and enhances the inhibitory effects of paclitaxel by promoting autophagy, apoptosis, and G2/M cell cycle arrest. PMID: 21244707
  34. These data highlighted an important role for ARHI in controlling hepatocellular carcinoma growth and angiogenesis. PMID: 21093415
  35. DIRAS3 gene is imprinted, with monoallelic expression from the paternal allele. PMID: 9874798
  36. Data show that ARHI could compete for Ran-importin binding and induce disruption of importin-binding to cargo proteins, including STAT3. PMID: 19435463
  37. A link between NOEY2 loss expression and the spreading mechanism of breast cancer may possibly exist. PMID: 12485503
  38. ARHI inhibits cell growth, and loss of its expression in cells may contribute to the development of breast and ovarian cancers PMID: 12771940
  39. Hypermethylation of CpG island II in the promoter region of ARHI is associated with the complete loss of ARHI expression in breast cancer cells. PMID: 12874023
  40. ARHI may have a role in development and progression of ductal breast carcinoma in situ PMID: 14506155
  41. Association between STAT3 and ARHI as well as the functional inhibition of STAT3 transcriptional activity by ARHI suggests a novel mechanism through which a putative tumor suppressor gene can inhibit STAT3 activity in breast and ovarian cancers. PMID: 16061651
  42. Down-regulation of ARHI gene is associated with breast cancer PMID: 16158053
  43. Down-regulation of ARHI due to loss of heterozygosity and promoter methylation is associated with ovarian cancers PMID: 18286529
  44. DIRAS3 is a novel, prognostically relevant candidate gene that is frequently methylated and silenced in oligodendroglial tumors with 1p deletion. PMID: 18302158
  45. provide evidences that ARHI downregulated in HCCs could play a role in liver cancer via acting as a tumor suppressor gene, which mainly was triggered by the epigenetic events in HCC specimens PMID: 18612997
  46. ARHI can induce autophagic cell death, but can also promote tumor dormancy in the presence of factors that promote survival in the cancer microenvironment. PMID: 19033662
  47. The presence of NOEY2 mutations in human breast cancer and early-stage lesions indicates that NOEY2 mutations may be partly associated with breast tumourigenesis. PMID: 19482475
  48. ARHI represents a modulator of cancer cell proliferation and may play an important role in the development of pancreatic cancer. PMID: 19639215
  49. Loss of heterozygosity at 1p31 (including ARHI) did not correlate with the mitotic activity index nor provide prognostic information. PMID: 19759414


Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

Recently viewed